Final results from a large-scale Phase III trial of the RTS,S malaria vaccine candidate, including the impact of a booster dose, published today in The Lancet, show that the vaccine candidate helped protect children and infants from clinical malaria for at least three years after first vaccination. … [Read more...]
GlaxoSmithKline Applies for Approval of RTS,S Malaria Vaccine
A “pretty good” malaria vaccine is on track to be the first to market. It only prevents infection about one-quarter to one-half the time, so it’s not as good as most vaccines. But for a disease like malaria, which kills 600,000 people a year, “pretty good” may be good enough. GlaxoSmithKline has applied for regulatory approval for its RTS,S vaccine. Partial protection A new 18-month study in … [Read more...]
GlaxoSmithKline Seeks to Market RTS,S Malaria Vaccine
British drugmaker GlaxoSmithKline is seeking approval to market the world's first malaria vaccine, after trials showed that it significantly cut cases of the disease in children. Results from latest clinical trial of the RTS,S vaccine were unveiled at a conference in Durban, South Africa on Tuesday. It showed that after 18 months of follow-up, the vaccine halved the number of malaria cases … [Read more...]
Phase III Trial of RTS,S Malaria Candidate Vaccine Reduces Malaria by One Third
Results from a pivotal, large-scale Phase III trial, published online today in the New England Journal of Medicine, show that the RTS,S malaria vaccine candidate can help protect African infants against malaria. When compared to immunization with a control vaccine, infants (aged 6-12 weeks at first vaccination) vaccinated with RTS,S had one-third fewer episodes of both clinical and severe malaria … [Read more...]
Glaxo’s RTS,S Malaria Vaccine Shows Promise
Preliminary results from the trial of a malaria vaccine show that it protected nearly half of the children who received it from bouts of serious malaria, scientists said Tuesday. The vaccine, known as RTS,S and made by GlaxoSmithKline, has been in development for more than 25 years, initially for the American military and now with most of its support from the Bill and Melinda Gates Foundation. … [Read more...]
Study Finds Malaria Vaccine Candidate, RTS,S Significantly Reduces Malaria Risk in African Infants
First results from a large-scale Phase III trial of RTS,S*, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & … [Read more...]
RTS,S Malaria Vaccine
QUESTION: What information can you provide on this vaccine candidate? ANSWER: RTS,S is a vaccine candidate against Plasmodium falciparum malaria which works by encouraging the host's body to produce antibodies and T cells which diminish the malaria parasite's ability to survive and reproduce in the liver. Produced by GlaxoSmithKline, RTS,S is the first vaccine candidate against … [Read more...]